UF Startup TearClear Appoints Robert J. Dempsey as CEO

UF startup TearClear, a global Ophthalmic Pharmaceutical Company, announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear, a resident client at UF Innovate | Sid Martin Biotech, is the only pharmaceutical company to administer preservative-free eye drops to the ocular surface, that are preserved safely prior to dosing.

Dempsey, who has more than two decades of experience in the ophthalmic pharmaceutical industry, is expected to accelerate TearClear’s business and commercial strategy, including advancing the robust pipeline and leading the company’s efforts in bringing innovative products to market.

Read more about UF Startup TearClear Appoints Robert J. Dempsey as CEO.